Scarica l'app Stockscreener
0.9597
3.96%
0.0551
Precedente Chiudi:
$0.9046
Aprire:
$0.914
Volume 24 ore:
229.48K
Relative Volume:
0.18
Capitalizzazione di mercato:
$204.99M
Reddito:
-
Utile/perdita netta:
$-179.82M
Rapporto P/E:
-0.4343
EPS:
-2.21
Flusso di cassa netto:
$-159.16M
1 W Prestazione:
+10.18%
1M Prestazione:
+28.86%
6M Prestazione:
-2.02%
1 anno Prestazione:
-3.05%
Intervallo 1D:
$0.9101
$0.9597
Intervallo di 1 settimana:
$0.808
$0.9475
Portata 52W:
$0.4993
$1.60
Gossamer Bio Inc Stock (GOSS) Company Profile
Nome
Gossamer Bio Inc
Settore
Industria
Telefono
(858) 922-0718
Indirizzo
3013 SCIENCE PARK, SAN DIEGO, CA
Confronta GOSS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GOSS
Gossamer Bio Inc
|
0.9597 | 204.99M | 0 | -179.82M | -159.16M | -1.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
406.51 | 103.71B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.00 | 78.28B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
625.42 | 36.77B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
236.59 | 30.35B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
115.80 | 27.32B | 3.30B | -501.07M | 1.03B | -2.1146 |
Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-06-25 | Iniziato | Oppenheimer | Outperform |
| 2024-04-05 | Ripresa | Wedbush | Outperform |
| 2023-07-27 | Downgrade | UBS | Buy → Neutral |
| 2023-03-07 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-03-01 | Iniziato | Guggenheim | Neutral |
| 2022-12-07 | Downgrade | Barclays | Overweight → Equal Weight |
| 2022-12-07 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-12-07 | Downgrade | SMBC Nikko | Outperform → Neutral |
| 2022-10-20 | Iniziato | Goldman | Buy |
| 2022-09-21 | Iniziato | JP Morgan | Neutral |
| 2022-09-19 | Iniziato | Wedbush | Outperform |
| 2022-04-18 | Iniziato | Raymond James | Outperform |
| 2022-04-06 | Iniziato | UBS | Buy |
| 2022-01-10 | Aggiornamento | SMBC Nikko | Neutral → Outperform |
| 2021-11-09 | Ripresa | Cantor Fitzgerald | Overweight |
| 2021-09-21 | Ripresa | Piper Sandler | Overweight |
| 2020-06-29 | Iniziato | H.C. Wainwright | Buy |
| 2020-04-22 | Iniziato | Piper Sandler | Overweight |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-30 | Iniziato | Berenberg | Buy |
| 2019-03-05 | Iniziato | Barclays | Overweight |
| 2019-03-05 | Iniziato | BofA/Merrill | Buy |
| 2019-03-05 | Iniziato | Evercore ISI | Outperform |
| 2019-03-05 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Gossamer Bio Inc Borsa (GOSS) Ultime notizie
3 US Penny Stocks With Market Caps Over $100M - Simply Wall St
Gossamer Bio, Inc. (NASDAQ:GOSS) Sees Large Increase in Short Interest - MarketBeat
Gossamer Bio, Inc. (NASDAQ:GOSS) Short Interest Up 10.0% in December - Defense World
Gossamer Bio (GOSS) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
The Manufacturers Life Insurance Company Boosts Stock Position in Gossamer Bio, Inc. (NASDAQ:GOSS) - Defense World
US Penny Stocks: 3 Picks With Market Caps Under $200M - Simply Wall St
XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio - The Manila Times
XOMA Royalty Acquires Pulmokine for $20 Million Adding the - GlobeNewswire
XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio - Benzinga
Gossamer Bio: Q3 Earnings Snapshot - Marketscreener.com
Adicet Bio Inc (NASDAQ: ACET) – Analysts’ Revisions Point To Positive Sentiment - Stocks Register
GSA Capital Partners LLP Invests $67,000 in Gossamer Bio, Inc. (NASDAQ:GOSS) - Defense World
Gossamer Bio Inc (GOSS)Monday, Aug 26, 2024 - Smartkarma
All You Need to Know About Gossamer Bio (GOSS) Rating Upgrade to Buy - MSN
US Bancorp DE Makes New $39,000 Investment in Gossamer Bio, Inc. (NASDAQ:GOSS) - Defense World
After Plunging -20% in 4 Weeks, Here's Why the Trend Might Reverse for Gossamer Bio (GOSS) - Yahoo Finance
Leerink Partnrs Raises Earnings Estimates for Gossamer Bio - Defense World
After Plunging -15.92% in 4 Weeks, Here's Why the Trend Might Reverse for Gossamer Bio (GOSS) - Yahoo Finance
HC Wainwright Increases Earnings Estimates for Gossamer Bio - MarketBeat
FMR LLC's Strategic Acquisition of Gossamer Bio Inc Shares - GuruFocus.com
Industry Analysts Just Made A Sizeable Upgrade To Their Gossamer Bio, Inc. (NASDAQ:GOSS) Revenue Forecasts - Yahoo Finance
Gossamer Bio (GOSS) Reports Q3 Loss, Tops Revenue Estimates - MSN
Gossamer Bio Grants 183K Stock Options to New Hires at $0.88 Per Share | GOSS Stock News - StockTitan
Gossamer Bio (NASDAQ:GOSS) Earns Buy Rating from HC Wainwright - MarketBeat
Gossamer Bio, Inc. (NASDAQ:GOSS) Just Reported And Analysts Have Been Lifting Their Price Targets - Yahoo Finance
Gossamer Bio Reports Revenue Growth Amid Strategic Collaborations - TipRanks
GOSSGossamer Bio, Inc. Latest Stock News & Market Updates - StockTitan
Gossamer Bio Announces Third Quarter 2024 Financial Results and Provides Business Update - Business Wire
Presenting on the Emerging Growth Conference 76 Day 2 on October 31 Register Now - The Manila Times
Gossamer Bio, Inc. (NASDAQ:GOSS) Short Interest Update - MarketBeat
Gossamer Bio, Inc. (NASDAQ:GOSS) Sees Large Decline in Short Interest - Defense World
Tevogen Bio Signs Letter of Intent With CD8 Technology to Build Up to a $50 Million R&D and Manufacturing Facility; No Impact on Shareholder Equity - Yahoo Finance
3 US Penny Stocks With Market Caps Under $900M To Consider - Simply Wall St
Gossamer Bio, Inc. (NASDAQ:GOSS) Shares Bought by The Manufacturers Life Insurance Company - Defense World
Hypertension Clinical Trials 2024: FDA Approvals, Medication, Therapies, MOA, ROA, Companies by DelveInsight | Quantum Genomics, CinCor Pharma, Mineralys Therapeutics, Alnylam Therapeutics, Novartis - The Globe and Mail
It makes sense and dollars to buy Gossamer Bio Inc (GOSS) stock - SETE News
Financial Fitness Check: Examining Gossamer Bio Inc (GOSS)’s Key Ratios - The Dwinnex
Gossamer Bio Inc (GOSS) rating initates by Oppenheimer - Knox Daily
Millennium Management LLC Sells 898,042 Shares of Gossamer Bio, Inc. (NASDAQ:GOSS) - MarketBeat
Gossamer Bio, Inc. (NASDAQ:GOSS) Shares Sold by Millennium Management LLC - MarketBeat
The Attractiveness of Investing In Gossamer Bio Inc (GOSS) is Growing - Knox Daily
Investor’s Delight: Gossamer Bio Inc (GOSS) Closes Weak at 1.02, Down -2.86 - The Dwinnex
GOSS underperforms with a -2.86 decrease in share price - US Post News
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - BioSpace
Gossamer Bio Inc [NASDAQ: GOSS] Sees Decrease in Stock Value - Knox Daily
Marshall Wace LLP Boosts Position in Gossamer Bio, Inc. (NASDAQ:GOSS) - MarketBeat
Several Insiders Invested In Gossamer Bio Flagging Positive News - Yahoo Finance
Analyzing Northwest Biotherapeutics (OTCMKTS:NWBO) and Gossamer Bio (NASDAQ:GOSS) - Defense World
Navigating GOSS’s Stock Market Maze: Ups and Downs in 2023 - The InvestChronicle
Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc. - Yahoo Finance
A better buy-in window may exist right now for Gossamer Bio Inc (GOSS) - SETE News
Gossamer Bio Inc Azioni (GOSS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Gossamer Bio Inc Azioni (GOSS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Hasnain Faheem | President & CEO |
Jun 21 '24 |
Buy |
0.67 |
372,000 |
250,282 |
5,408,073 |
| Giraudo Bryan | COO/CFO |
Jun 18 '24 |
Buy |
0.59 |
100,000 |
59,110 |
480,010 |
| Smith Robert Paul JR | Chief Commercial Officer |
Jun 17 '24 |
Buy |
0.60 |
25,000 |
15,050 |
25,000 |
| Christian Waage | EVP, Tech Ops and Admin |
Mar 27 '24 |
Sale |
1.16 |
6,430 |
7,430 |
585,934 |
| Giraudo Bryan | COO/CFO |
Mar 27 '24 |
Sale |
1.16 |
6,430 |
7,431 |
92,737 |
| Hasnain Faheem | President & CEO |
Mar 27 '24 |
Sale |
1.16 |
23,172 |
26,773 |
120,293 |
| Aranda Richard | Chief Medical Officer |
Mar 18 '24 |
Sale |
1.33 |
4,018 |
5,342 |
198,799 |
| Peterson Caryn | EVP, Regulatory Affairs |
Mar 18 '24 |
Sale |
1.33 |
4,018 |
5,343 |
49,833 |
0.93%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):